Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Kinnate Biopharma Inc | KNTE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.65 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.65 | 2.65 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.04 - 4.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.65 | USD |
Kinnate Biopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 125.15M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Kinnate Biopharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KNTE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 2.64 | 2.69 | 2.64 | 2.65 | 1,166,347 | 0.01 | 0.38% |
| 3 Months | 2.33 | 2.69 | 2.20 | 2.56 | 496,209 | 0.32 | 13.73% |
| 6 Months | 1.17 | 2.69 | 1.04 | 2.46 | 966,881 | 1.48 | 126.50% |
| 1 Year | 2.90 | 4.50 | 1.04 | 2.61 | 643,266 | -0.25 | -8.62% |
| 3 Years | 26.70 | 27.65 | 1.04 | 6.22 | 308,821 | -24.05 | -90.07% |
| 5 Years | 40.00 | 48.75 | 1.04 | 8.79 | 298,995 | -37.35 | -93.38% |
Kinnate Biopharma Description
| Kinnate Biopharma Inc a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's product candidate is KIN-2787, which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor it is developing for the treatment of patients with lung cancer, melanoma and other solid tumors. Its KIN003 program is evaluating Fibroblast Growth Factor Receptors (FGFR) inhibitor candidates for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining. |
